Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GBS-NN

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $57.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing December 15, 2020

            Details:

            Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.